COVID-19 Infection in Men on Testosterone Replacement Therapy. Issue 1 (9th October 2020)

• Record Type: Journal Article
• Authors: Rambhatla, Amarnath; Bronkema, Chandler J.; Corsi, Nicholas; Keeley, Jacob; Sood, Akshay; Affas, Ziad; Dabaja, Ali A.; Rogers, Craig G.; Liroff, Stephen A.; Abdollah, Firas
• Is Part Of: Journal of sexual medicine. Volume 18:Issue 1(2021)
• Page Start: 215
• Page End: 218
• Publication Date: 2020-10-09
• Subjects: Androgens -- COVID-19 -- Hypogonadism -- SARS-CoV-2 -- Testosterone -- Testosterone Replacement Therapy -- Venous Thromboembolism; Sexual disorders -- Periodicals; Sex -- Periodicals; Sexual health -- Periodicals; 616.69005
• DOI: 10.1016/j.jsxm.2020.09.013
• Languages: English
• ISSNs: 1743-6095

Abstract

ABSTRACT: Background: Men who contract coronavirus disease 2019 (COVID-19) appear to have worse clinical outcomes compared with women which raises the possibility of androgen-dependent effects. Aim: We sought to determine if testosterone replacement therapy (TRT) is associated with worse clinical outcomes. Methods: Through a retrospective chart review, we identified 32 men diagnosed with COVID-19 and on TRT. They were propensity score matched to 63 men diagnosed with COVID-19 and not on TRT. Data regarding comorbidities and endpoints such as hospital admission, intensive care unit admission, ventilator utilization, thromboembolic events, and death were extracted. Chi-square and Kruskal-Wallis tests examined differences in categorical and continuous variables, respectively. Logistic regression analysis tested the relationship between TRT status and the study endpoints. Results: There were no statistically significant differences between the 2 groups, and TRT was not a predictor of any of the endpoints on multivariate analysis. Conclusion: These results suggest that TRT is not associated with a worse clinical outcome in men diagnosed with COVID-19.